Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 5/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31554494 | 0.85 | KIT (0.45) | KITPDGFRBPDGFRAPDPK1SRC | |
| SCHEMBL31554419 | 0.85 | KIT (0.54) | KITPDGFRBPDGFRAPDPK1SRC | |
| SCHEMBL31554530 | 0.80 | PDGFRB (0.41) | KITPDGFRBPDGFRAPDPK1TRPA1 | |
| SCHEMBL14967538 | 0.80 | PDGFRB (0.57) | KITPDGFRBPDGFRAKDREGFR | |
| SCHEMBL31554537 | 0.78 | AXL (0.51) | KITPDPK1SRCKDRTRPA1 | |
| SCHEMBL31554548 | 0.76 | AXL (0.45) | KITPDGFRBPDGFRAPDPK1KDR | |
| SCHEMBL24009146 | 0.74 | PDPK1 (0.47) | KITPDGFRBPDGFRAPDPK1KDR | |
| SCHEMBL25278689 | 0.73 | AXL (0.50) | PDGFRBPDGFRAEGFR | |
| SCHEMBL25258996 | 0.73 | PDGFRB (0.49) | KITPDGFRBPDGFRAKDREGFR | |
| SCHEMBL5054175 | 0.72 | SRC (0.60) | KITSRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096463-A1 | PLK4 MODULATORS | VIBLIOME THERAPEUTICS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |